touchONCOLOGY are joined by Dr Petros Grivas (University of Washington Medicine, Seattle, WAS, USA) to discuss results from Cohort 3 of the TROPHY-U-01 Study: Sacituzumab govitecan (SG) in combination with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Questions
- What is the rationale for the combination of immune checkpoint inhibitors and antibody-drug conjugates in metastatic urothelial cancer? (00:15-02:14)
- Could you give us a brief overview of the TROPHY-U-01 study? (02:15-03:34)
- What was the patient population of cohort 3 and what were the efficacy and safety findings? (03:35-07:42)
- What were the conclusions of the investigators? (07:43-09:36)
Speaker Disclosure: Dr Petros Grivas discloses consultancy/advisory board participation for Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Seattle Genetics, Pfizer, Janssen, Exelixis, Roche, Genentech, Dyania Health, Mirati Therapeutics, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, Regeneron Pharmaceuticals, Astellas Pharma, Guardant Health, Urogen pharma and Gilead Sciences. Dr Petros Grivas also disclosed research funding from Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Bristol-Myers Squibb, Debiopharm Group, Merck, QED Therapeutics, Kure It Cancer Research, GlaxoSmithKline, Mirati Therapeutics, EMD Serono and G1 Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Genitourinary Cancers Symposium 2022
